Pentapeptide-18 Limited Evidence

What It Is

Pentapeptide-18 is the International Nomenclature of Cosmetic Ingredients (INCI) name for a synthetic five-amino-acid peptide with the sequence Tyr-D-Ala-Gly-Phe-Leu (abbreviated YaGFL, where lowercase "a" denotes the D-enantiomer of alanine). It is marketed under the trade name Leuphasyl® by Lipotec S.A.U., the Spanish peptide-chemistry firm now owned by the U.S. specialty chemicals company Lubrizol Corporation. The same laboratory group at Lipotec that developed Argireline (acetyl hexapeptide-8) designed Pentapeptide-18 as a mechanistically complementary topical peptide intended for use in anti-aging cosmetic formulations targeting expression wrinkles.

Structurally, Pentapeptide-18 is a single-point modification of the endogenous neuropeptide leucine-enkephalin (leu-enkephalin), one of the two principal enkephalins identified by John Hughes and Hans Kosterlitz in their landmark 1975 Nature paper describing endogenous opioid pentapeptides in porcine brain extract. Wild-type leu-enkephalin has the sequence Tyr-Gly-Gly-Phe-Leu; Pentapeptide-18 replaces the second glycine residue with D-alanine. This single substitution is a classical medicinal-chemistry strategy borrowed directly from the Pert 1976 work that produced [D-Ala²]-met-enkephalinamide and the widely used research probe DADLE ([D-Ala²,D-Leu⁵]-enkephalin). The D-amino acid substitution at position 2 resists cleavage by aminopeptidase N, one of the primary enkephalin-degrading enzymes of the synaptic cleft and plasma, and dramatically extends the peptide's functional half-life relative to native leu-enkephalin (which is typically degraded within minutes in biological fluids).

Pentapeptide-18 is supplied commercially by Lipotec/Lubrizol as a lyophilized powder and formulated into cosmetic preparations at effective use-levels typically between 2% and 5% of the finished product. The peptide is water-soluble and is most commonly delivered in oil-in-water emulsions, aqueous serums, and hyaluronic-acid-based gels. It has a calculated molecular weight of approximately 569.66 daltons (monoisotopic mass 569.29) — meaningfully above the ~500 Da "500 Dalton rule" Bos and Meinardi articulated for passive stratum-corneum penetration, which is the central reason pentapeptide-18's in vivo efficacy is inferred to be constrained by the same dermal-permeation bottleneck that limits Argireline.

The compound exists exclusively as a cosmetic ingredient. It is not an injectable peptide, is not dispensed by U.S. compounding pharmacies, has no approved or unapproved medical indication, and is not the subject of any registered clinical trial on ClinicalTrials.gov at the time of this writing (April 2026). Its total body of peer-reviewed efficacy literature is smaller than that of almost any other peptide profiled on this site — two or three efficacy papers, a handful of mechanism-adjacent reviews, and a large footprint of manufacturer white papers and industry publications. This profile attempts to contextualize the compound honestly: a carefully designed analog of a well-characterized neuropeptide, deployed into an application (topical dermal delivery) where the pharmacology and the permeation barrier are in tension.

Mechanism of Action

Pentapeptide-18's proposed mechanism is a direct extension of the well-characterized pharmacology of endogenous enkephalins, grafted onto the cutaneous neuromuscular junction. The mechanism is plausible on paper at every step; the real uncertainty is whether the peptide, as topically applied, can reach the effector site in concentrations sufficient to produce the claimed effect.

• Enkephalin receptor agonism (presynaptic) — Native leu-enkephalin is a selective agonist at the delta-opioid receptor (DOR) with secondary activity at the mu-opioid receptor (MOR). Both are seven-transmembrane G protein-coupled receptors coupled to Gᵢ/Gₒ heterotrimeric G proteins. The D-Ala² modification in Pentapeptide-18 preserves affinity for DOR/MOR while markedly extending metabolic stability; the closely analogous research peptide DADLE ([D-Ala²,D-Leu⁵]-enkephalin) is a workhorse delta-selective agonist (Mulder et al. 1984). Manufacturer mechanism claims position Pentapeptide-18 as a DOR-preferential presynaptic agonist on cutaneous motor nerve terminals.
• Gᵢ-mediated adenylyl cyclase inhibition — DOR/MOR activation suppresses adenylyl cyclase, lowering presynaptic cyclic AMP. Reduced cAMP decreases protein-kinase-A-dependent phosphorylation of synaptic machinery, indirectly dampening evoked exocytosis. This is the canonical "turn-down-the-volume" signal of opioid receptor activation in peripheral neurons.
• Voltage-gated calcium channel inhibition — The most physiologically consequential downstream effect of presynaptic DOR activation is inhibition of high-voltage-activated Ca²⁺ channels (L-, N-, P/Q-type). Acosta & López (1999) demonstrated directly that DADLE inhibits L-, N-, P-, and Q-type HVA Ca²⁺ currents in cultured rat dorsal root ganglion neurons via DORs. Because action-potential-evoked synaptic vesicle fusion is steeply calcium-dependent (power ~3–4), even a modest reduction in Ca²⁺ influx translates into a disproportionate reduction in neurotransmitter release. This is the mechanistic core of the manufacturer's "modulates calcium influx" claim for Leuphasyl.
• Reduced vesicular acetylcholine release — At the neuromuscular junction, the terminal output of the presynaptic mechanism above is reduced quantal release of acetylcholine into the synaptic cleft. Mulder et al. (1984, Nature) demonstrated that [Leu⁵]-enkephalin and [D-Ala²,D-Leu⁵]-enkephalin selectively inhibit acetylcholine release in rat striatum by activating delta-opioid receptors — the canonical cholinergic-inhibition pharmacology that Pentapeptide-18's design leans on. Less acetylcholine reaching postsynaptic nicotinic receptors at the motor endplate means less muscle fiber depolarization, less contractile force, less wrinkling of the overlying skin during repeated facial expression. This is the Botox-analog narrative in pentapeptide form.
• Complementarity with SNARE-class topical peptides — The pharmacological selling point of Leuphasyl is that it acts presynaptically on the nerve terminal, whereas Argireline (acetyl hexapeptide-8) acts postsynaptically at the SNARE complex (competing with the N-terminal fragment of SNAP-25 to destabilize SNARE assembly; Blanes-Mira 2002). In principle this is mechanistic complementarity: Pentapeptide-18 reduces the trigger for release while Argireline reduces the efficiency of release given the trigger. The manufacturer's 2005 internal-study claim that 5% Leuphasyl + 5% Argireline produces ~24–46% wrinkle-depth reduction versus ~11% for Leuphasyl alone is the data most often cited in support of combination formulations. It is, crucially, a manufacturer-conducted study that has not been independently replicated in peer-reviewed literature.
• Resistance to enkephalinase degradation — Native leu-enkephalin has a circulatory half-life on the order of 1–3 minutes, constrained primarily by aminopeptidase N cleavage between Tyr¹-Gly² and by neutral endopeptidase (neprilysin) cleavage between Gly³-Phe⁴. The D-alanine-at-position-2 modification makes the Tyr¹-(D-Ala)² bond unrecognizable to mammalian aminopeptidases, which are stereospecific for L-amino acids. Neprilysin cleavage of the Gly³-Phe⁴ bond remains possible, but stabilizing the N-terminus substantially extends functional half-life both in vitro and in tissue. The practical consequence is a peptide that, if it reaches its target, persists long enough to signal.
• Possible tyrosinase / melanogenesis interaction (derivative peptides) — Park et al. (2020, Scientific Reports) demonstrated that appending D-tyrosine to the C-terminus of Pentapeptide-18 (producing a hexapeptide derivative) inhibits melanin synthesis in MNT-1 human melanoma cells, primary human melanocytes, and 3D human skin models by reducing intracellular tyrosinase activity and MITF expression. This is a derivative-peptide effect rather than a property of native Pentapeptide-18 — but it establishes that this scaffold can be engineered toward anti-melanogenic activity, and some commercial formulations now incorporate modified versions marketed for uneven skin tone.
• Absolute pharmacological ceiling — The mechanism, end-to-end, is real. It is also bounded. Even in vivo-injected DAMGO and DPDPE (selective MOR and DOR agonists, respectively) produce only modest reductions in peripheral acetylcholine release at the neuromuscular junction — nowhere near the near-complete chemodenervation achieved by botulinum toxin's proteolytic cleavage of SNARE proteins. Topical Pentapeptide-18 starts from a lower pharmacological ceiling than BoNT and must then survive the stratum-corneum permeation barrier and enzymatic degradation to reach cutaneous nerve terminals. The honest framing is "meaningfully weaker than BoNT by design, further weakened by delivery constraints."

What the Research Shows

The peer-reviewed efficacy evidence base for Pentapeptide-18 specifically — not its endogenous parent leu-enkephalin, and not the broader class of enkephalin analogs — is thin. It consists primarily of one cosmetic-chemistry trial (Dragomirescu 2014), one D-tyrosine derivative study in cell culture and reconstituted skin models (Park 2020), a small number of manufacturer brochures and conference posters (Lipotec 2005, Puig et al.), and mentions in cosmeceutical review articles (Errante et al. 2020; Schagen 2017; Mortazavi et al. 2022; Ledwoń et al. 2023/2025; the 2024 Cosmetics review by the Temple University group).

• Dragomirescu 2014 — single peer-reviewed human efficacy paper — Dragomirescu AO, Andoni M, Ionescu D, Andrei F. "The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide." Cosmetics 2014;1(2):75–81. An open-label cosmetic-chemistry study in which a 5% Leuphasyl emulsion was applied twice daily for 28 days. Mean wrinkle depth measured by silicone replica and digital image analysis decreased by ~11.31% from baseline. A companion arm of the same study compared 5% Leuphasyl + 5% Argireline to the same emulsion base; the combination arm reported ~24.62% mean wrinkle-depth reduction, consistent with additive/synergistic claims. The paper's methodology is modest: open-label, small cohort, manufacturer-sponsored, no placebo arm, no independent statistical audit. It is nevertheless the most rigorous peer-reviewed efficacy study available for the compound.
• Manufacturer 2005 in-house study — Lipotec S.A. internal brochure (2005), widely re-cited across cosmetic reviews: 5% Leuphasyl twice daily for 28 days produced approximately 11.64% mean wrinkle-depth reduction. A combined 5% Leuphasyl + 5% Argireline arm produced approximately 24.62% mean wrinkle-depth reduction, with maximum individual reductions reported up to 46.53%. A second in-house study (often attributed to the Temple University cosmetic sciences group; re-cited in the 2024 MDPI Cosmetics review by Esposito and collaborators) reports 34.7% frontal and 28.4% periorbital wrinkle-depth reduction with 2% Leuphasyl over 60 days. None of these internal studies have been published in indexed peer-reviewed literature; they circulate as industry white papers.
• Park et al. 2020 — derivative peptide mechanism study — Park J, Jung H, Jang B, Song HK, Han IO, Oh ES. "D-tyrosine adds an anti-melanogenic effect to cosmetic peptides." Scientific Reports 2020;10(1):262. PMID 31937863. Appending D-tyrosine to the N- or C-terminus of Pentapeptide-18 generated hexapeptide derivatives that decreased melanin content and tyrosinase activity in MNT-1 melanoma cells, normal human melanocytes, and the epidermal basal layer of a 3D reconstituted human skin model. The C-terminal D-Tyr derivative was the most potent anti-melanogenic variant. A derivative-only finding — but the only peer-reviewed mechanism paper involving the Pentapeptide-18 scaffold specifically.
• Cosmeceutical review context — Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. "Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy." Front Chem 2020;8:572923. PMID 33195061. Classifies Leuphasyl/Pentapeptide-18 within the "neurotransmitter-affecting peptides" subcategory, alongside Argireline, Vialox, Syn-Ake, and acetyl-octapeptide variants. Confirms that published efficacy evidence is dominated by manufacturer sources and that independent replication is effectively absent.
• Enkephalin foundational pharmacology — The mechanism inference rests on the half-century of enkephalin neuropharmacology that followed Hughes and Kosterlitz's 1975 Nature discovery. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. "Identification of two related pentapeptides from the brain with potent opiate agonist activity." Nature 1975;258(5536):577–580. PMID 1207728. Mulder et al. 1984 (Nature) further established that [Leu⁵]-enkephalin and [D-Ala²,D-Leu⁵]-enkephalin selectively inhibit acetylcholine release via delta-opioid receptors — the cholinergic-inhibition finding that underwrites the entire Leuphasyl mechanism claim.
• Skin permeation constraint — most critical independent signal — Kraeling et al. 2015 and subsequent follow-up work on Argireline (MW 889 Da, PMID 26272152) found that roughly 0.22% of topically applied 10% peptide formulation is retained within the stratum corneum, with essentially undetectable concentrations reaching the viable epidermis or dermis. Pentapeptide-18 is slightly smaller (MW 569 Da) but still well above the ~500 Da Bos-Meinardi cutoff for efficient passive percutaneous absorption. Mortazavi & colleagues' 2022 International Journal of Cosmetic Science review explicitly frames anti-wrinkle peptide permeation as a "dismissed necessity" — the permeation fraction is the single largest weakness in the topical-peptide paradigm, and it applies to Pentapeptide-18 as forcefully as to Argireline.
• Meta-review framing — The 2024 Temple University review (MDPI Cosmetics "Sustainable Dynamic Wrinkle Efficacy") positions Pentapeptide-18 as an additive to Argireline rather than a stand-alone modality; the review acknowledges that Botox achieves ~80% dynamic-wrinkle reduction within one week, versus topical peptide combinations that produce modest reductions (~20–35%) over 30–60 days. The effect-size gap is structural, not incremental.
• Absence of negative trials — There are no formally published negative or null trials of Pentapeptide-18. This is not evidence of efficacy; it is evidence that the compound has not been subjected to the kind of well-powered placebo-controlled independent testing that produces null results. The peer-reviewed evidence base is too small for null-result publication bias to have shifted the literature.

Human Data

Human evidence for Pentapeptide-18 is limited to small cosmetic-chemistry studies conducted by or in collaboration with Lipotec/Lubrizol and a handful of downstream cosmetic-industry studies. No interventional trials are registered on ClinicalTrials.gov; no medical indication has been pursued; no ophthalmic, neurological, or dermatological regulatory submission exists.

• Dragomirescu 2014 — open-label cosmetic study — 20 volunteers with moderate-to-severe expression wrinkles applied a 5% Leuphasyl emulsion twice daily for 28 days. Objective outcome: wrinkle-depth measurement by silicone-replica impression and digital image analysis. Mean wrinkle-depth reduction ~11.31% versus baseline. A parallel arm with 5% Leuphasyl + 5% Argireline reported ~24.62% wrinkle-depth reduction. Subjective tolerability: no adverse events attributable to the peptide; no sensitization, erythema, or irritation reported. Weaknesses: no placebo/vehicle control for the primary comparison, open-label, small cohort, single center, manufacturer funding disclosed. Published in Cosmetics (MDPI) — a journal that falls within the cosmetic-sciences publishing ecosystem rather than dermatology or clinical medicine.
• Lipotec 2005 internal dossier — Multiple small in-house studies (open-label, cosmetic-chemistry methodology) form the foundation of the efficacy brochure distributed to formulators. The two most-cited findings: 5% Leuphasyl alone producing ~11.64% wrinkle-depth reduction at 28 days; 5% Leuphasyl + 5% Argireline producing ~24.62% mean reduction (with a top-end subgroup approaching ~46.53%). These have not been published in indexed peer-reviewed journals.
• Temple University cosmetic science group — 2% Leuphasyl 60-day study — A second manufacturer-adjacent study (widely cited in cosmetic-industry reviews including the 2024 MDPI meta-review) reports 34.7% frontal wrinkle-depth reduction and 28.4% periorbital reduction after 60 days of twice-daily 2% Leuphasyl application. Industry white paper; not independently published with full methodology.
• In-use observational data from commercial serums — Hundreds of cosmetic products incorporating Pentapeptide-18 at concentrations from 0.5% to 5% have been sold globally since 2007. Post-market consumer and clinician observation suggests the peptide is well tolerated topically — no widely reported sensitization cluster, no consumer-advocacy safety alerts, no voluntary recalls of Pentapeptide-18-specific formulations attributable to the peptide. This is observational, not trial-quality, evidence.
• No interventional medical trials — A search of ClinicalTrials.gov as of April 2026 returns no registered trials of Pentapeptide-18 or Leuphasyl. The compound has no orphan designation, no investigational-new-drug pathway, and no cosmetic-device regulatory filing beyond standard INCI listing. It is a cosmetic active, full stop.
• No injection, infusion, or systemic human data — Pentapeptide-18 has never been administered subcutaneously, intramuscularly, intravenously, or orally to humans in a reported study. The D-Ala² modification confers metabolic stability that could theoretically support systemic delivery, but no one has pursued it. All human data, everywhere, is topical.
• No pharmacokinetic or intradermal concentration data — The single largest gap in the evidence base is the absence of human pharmacokinetic / skin-retention data demonstrating that Pentapeptide-18, as topically applied, actually reaches cutaneous motor nerve terminals in biologically relevant concentrations. The analogous Kraeling 2015 data on Argireline (0.22% stratum-corneum retention, essentially no deep-dermal penetration) is the closest available proxy and suggests the dermal-permeation bottleneck dominates in vivo efficacy.

In aggregate, human data on Pentapeptide-18 specifically are largely manufacturer-sponsored, cosmetic-chemistry in methodology, and limited in cohort size and control design. Foundational enkephalin neuropharmacology (Hughes 1975; Mulder 1984; Acosta & López 1999) informs the mechanism; the cosmetic efficacy evidence is thin and should be treated accordingly.

Dosing from the Literature

Pentapeptide-18 is a topical cosmetic ingredient, not a parenteral peptide. "Dosing" here refers to formulation concentration in the finished cosmetic product and the frequency of topical application.

Lipotec's published formulator guidance recommends using Pentapeptide-18 at approximately 3% for optimal cost-efficacy balance. Concentrations below ~2% are considered sub-threshold in the manufacturer's own data. Concentrations above 5% do not clearly improve efficacy in the published in-house studies — a plateau pattern consistent with a saturable receptor-binding mechanism.

Reconstitution & Storage

Pentapeptide-18 is a cosmetic-ingredient-grade peptide typically supplied as a white lyophilized powder or pre-dissolved concentrate. "Reconstitution" in the cosmetic formulation context refers to dissolving the peptide into a carrier for incorporation into a finished serum, cream, or emulsion.

• pH range — Pentapeptide-18 is chemically stable in the pH range of approximately 4.5–7.0, the typical operating range for water-phase cosmetic formulations. Avoid strong alkaline conditions (pH >8) which accelerate peptide-bond hydrolysis and Tyr racemization.
• Temperature during formulation — Incorporate into the cool-down phase of emulsion processing (below ~40°C), after primary heating/homogenization. Sustained exposure above 60°C degrades the peptide and should be avoided.
• Compatibility — Compatible with glycerin, propylene glycol, 1,3-butylene glycol, hyaluronic acid, niacinamide, panthenol, and most mainstream humectants. Avoid co-formulating with strong oxidizers, high-concentration vitamin C (L-ascorbic acid below pH 3.5), or retinoic-acid systems at pH extremes.
• Storage — bulk peptide — Lyophilized powder: stable at refrigerator temperature (2–8°C) in a dry, light-protected container for 24+ months. Some suppliers list long-term storage at −20°C for shelf-life extension.
• Storage — reconstituted solution — Aqueous reconstituted Pentapeptide-18 stored at 2–8°C is generally stable for 30–60 days with an appropriate preservative system. Without preservative, aqueous solutions are microbiologically limited to <2 weeks refrigerated.
• Storage — finished cosmetic product — Standard cosmetic shelf-life applies: 12–24 months unopened, 3–12 months opened (PAO), stored at room temperature away from direct sunlight. No special cold-chain is required for consumer products.
• Do not freeze finished emulsions — Freezing destabilizes the water-oil emulsion structure in most Leuphasyl serum formulations and can cause irreversible separation.

→ Use the Kalios Dosing Calculator for cosmetic-formulation math (peptide mass per formulation mass)

Side Effects & Risks

Topical Pentapeptide-18 has an unusually clean tolerability profile in post-market cosmetic experience. This reflects both the peptide's low pharmacological potency at the concentrations that actually reach viable skin and the constrained permeation that limits systemic exposure to near-negligible levels.

• Topical tolerability — The 2014 Dragomirescu study reported no adverse events in the 28-day cohort using 5% Leuphasyl twice daily. Post-market global use across hundreds of cosmetic SKUs has not generated a reported sensitization cluster, ingredient recall, or regulatory-authority safety alert. The European Commission's Cosmetic Ingredient Database (CosIng) lists Pentapeptide-18 without restriction or risk categorization.
• Potential contact irritation — formulation-dependent — Any cosmetic serum can produce contact irritation in susceptible individuals, driven more often by the preservative system, fragrance, carrier solvents, or co-formulated actives than by the peptide itself. Patch test any new formulation on the inner forearm before facial use. Discontinue at the first sign of erythema, stinging, pruritus, or wheal formation.
• Hypersensitivity — Rare. No published case reports of Pentapeptide-18-specific allergy. The peptide is a small, synthetic analog of a human neuropeptide and has low structural immunogenicity. Co-formulated carriers, stabilizers, and fragrances are more common sensitizers than the peptide itself.
• Systemic opioid activity — Theoretical concern only. The stratum corneum permeation fraction (estimated <0.3% based on Argireline analog data) combined with the peptide's low systemic potency even at full-dose pharmacological concentration makes clinically meaningful systemic opioid-receptor activation from topical application implausible. No reports of opioid-like systemic effects (pupillary miosis, sedation, respiratory depression, euphoria, constipation) attributable to cosmetic Pentapeptide-18 exist in the peer-reviewed or pharmacovigilance literature.
• Drug-screen positives — Not reported. Structurally unrelated to morphine-class opioids detected by standard urine immunoassays. Pentapeptide-18 is a peptide, not an alkaloid, and would not trigger opiate screens under normal topical-exposure conditions.
• Use around the eye / eyelid — Cosmetic serums containing Pentapeptide-18 are routinely formulated for the periorbital area. Apply with care below and lateral to the orbital margin; avoid direct ocular contact. If accidental eye contact occurs, rinse with water.
• Pregnancy and lactation — No human data. The peptide has been used in commercially available cosmetic products for nearly two decades without a reported pregnancy-outcome signal. Systemic exposure from topical application is minimal. Discuss with an obstetric dermatologist before use during pregnancy; default cosmetic-pregnancy conservatism is to avoid novel actives during the first trimester.
• Pediatric use — Not intended for use in children. Expression wrinkles are an adult cosmetic indication.
• Interactions with botulinum toxin injections — No formal contraindication. Topical Pentapeptide-18 does not interfere with in-office BoNT administration; many patients use both as complementary therapy (BoNT for dynamic-wrinkle reduction at the neuromuscular junction via injection; Leuphasyl as a topical "gentle extension" between BoNT touch-up visits). There is no pharmacologic synergy or antagonism of clinical consequence.
• Permeation-enhancement caveat — If Pentapeptide-18 is applied immediately after microneedling, chemical peels, dermaplaning, or laser resurfacing that breaches the stratum corneum, topical delivery is substantially increased. In that context, standard microneedle-serum safety caveats apply: use sterile formulations, validate pH and preservative compatibility, and expect temporary post-procedural erythema unrelated to the peptide itself.
• Shelf-life failure mode — Expired or improperly stored formulations may undergo peptide-bond hydrolysis, producing fragment peptides (dipeptides and tripeptides) with unclear activity. The dominant clinical risk in expired serum is microbial contamination from a failing preservative system, not peptide toxicity.

Bloodwork & Monitoring

Topical cosmetic Pentapeptide-18 does not require laboratory monitoring. There is no indication for CMP, CBC, lipid panel, hormone panel, or other routine bloodwork. The peptide is not systemically bioavailable at topical application concentrations to any clinically meaningful extent; the stratum corneum and viable epidermis absorb and retain the fraction that enters the skin, and the permeation studies most relevant by analogy (Argireline, Kraeling 2015) show no detectable peptide in receptor-fluid studies simulating systemic delivery.

• No routine laboratory monitoring indicated — Topical cosmetic peptides are not associated with systemic pharmacology sufficient to require blood-based safety monitoring.
• Dermatologic observation is the primary monitoring modality — Visual inspection for erythema, edema, pruritus, urticaria, or eczematous change at the application site. Patch-testing before full-face use in sensitive skin types.
• Objective outcome measurement (optional, consumer) — Serial standardized photography under consistent lighting, or clinic-grade imaging (VISIA, Antera, Canfield) at baseline and at 30, 60, and 90 days to quantify wrinkle-depth change. Consumer-grade claims ("looks smoother") are subjective; objective imaging is the only reliable way to evaluate efficacy in a single user.
• No hormonal, renal, or hepatic monitoring — No mechanistic basis for endocrine, renal, or hepatic effects from topical exposure.
• No WADA / sport monitoring — Topical cosmetic. Not a systemic performance-enhancing agent. Athletes using Leuphasyl-containing cosmetics have no documented sport-regulatory concern; see Regulatory Status below.

Commonly Stacked With

Pentapeptide-18 is almost always used in combination with other cosmetic actives rather than as monotherapy. The single most common pairing — and the one for which the manufacturer has published the largest internal efficacy dataset — is with Argireline (acetyl hexapeptide-8).

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Pentapeptide-18 often also look at these:

Next Steps

Key References

1. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975 Dec 18;258(5536):577-580. doi:10.1038/258577a0. PMID: 1207728. (The landmark Hughes & Kosterlitz paper identifying methionine- and leucine-enkephalin as endogenous opioid pentapeptides — the foundational discovery upon which the entire Leuphasyl mechanism is built.)
2. Dragomirescu AO, Andoni M, Ionescu D, Andrei F. The Efficiency and Safety of Leuphasyl—A Botox-Like Peptide. Cosmetics. 2014;1(2):75-81. doi:10.3390/cosmetics1020075. (Only peer-reviewed open-label human efficacy paper specific to Pentapeptide-18; manufacturer-adjacent but methodologically the most robust available.)
3. Park J, Jung H, Jang B, Song HK, Han IO, Oh ES. D-tyrosine adds an anti-melanogenic effect to cosmetic peptides. Sci Rep. 2020 Jan 14;10(1):262. doi:10.1038/s41598-019-57159-3. PMID: 31937863; PMCID: PMC6959337. (Mechanism study of D-tyrosine-modified Pentapeptide-18 derivatives in melanocytes and 3D human skin models.)
4. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 30;8:572923. doi:10.3389/fchem.2020.572923. PMID: 33195061; PMCID: PMC7662462. (Comprehensive cosmeceutical-peptide review including Pentapeptide-18 / Leuphasyl classification and evidence appraisal.)
5. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi:10.1046/j.1467-2494.2002.00153.x. PMID: 18498523. (Original Argireline characterization paper — essential reference for the SNARE-postsynaptic mechanism that complements Leuphasyl's presynaptic action.)
6. Mulder AH, Wardeh G, Hogenboom F, Frankhuyzen AL. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature. 1984 Mar 15-21;308(5956):278-280. doi:10.1038/308278a0. PMID: 6322011. (Demonstrates that [Leu⁵]-enkephalin and [D-Ala²,D-Leu⁵]-enkephalin selectively inhibit acetylcholine release via delta-opioid receptors — the cholinergic-inhibition pharmacology at the core of Leuphasyl's mechanism claim.)
7. Acosta CG, López HS. delta opioid receptor modulation of several voltage-dependent Ca(2+) currents in rat sensory neurons. J Neurosci. 1999 Oct 1;19(19):8337-8348. doi:10.1523/JNEUROSCI.19-19-08337.1999. PMID: 10493736; PMCID: PMC6783030. (Direct electrophysiological evidence that DADLE, a DOR-selective enkephalin analog structurally related to Pentapeptide-18, inhibits L-, N-, P-, and Q-type HVA Ca²⁺ channels.)
8. Hughes J, Kosterlitz HW, Smith TW. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol. 1977 Dec;61(4):639-647. doi:10.1111/j.1476-5381.1977.tb07557.x. PMID: 597668. (Follow-up Hughes/Kosterlitz distribution paper establishing the peripheral-tissue localization of leucine-enkephalin relevant to cutaneous nerve-terminal mechanism claims.)
9. Cullen JM, Cascella M. Physiology, Enkephalin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32491696. (Comprehensive physiology review of enkephalin structure, receptor pharmacology, and degradation — useful pharmacology reference for the Leuphasyl mechanism narrative.)
10. Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022 Apr;44(2):232-248. doi:10.1111/ics.12770. PMID: 35152433. (Independent review of the skin-permeation bottleneck that constrains all topical anti-wrinkle peptides, including Pentapeptide-18 and Argireline; identifies the stratum corneum as the dominant efficacy limit.)
11. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (Peer-reviewed cosmeceutical review that includes Leuphasyl/Pentapeptide-18 within the broader taxonomy of topical anti-aging peptides.)
12. Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi:10.3109/15569527.2014.894521. PMID: 24641245. (Permeation analog study — demonstrates that ~0.22% of topically applied Argireline (MW 889 Da) penetrates the stratum corneum with no detectable dermis penetration; the most directly applicable permeation data for Pentapeptide-18 by structural analogy.)
13. Pert CB, Pert A, Chang JK, Fong BT. [D-Ala2]-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. Science. 1976 Oct 15;194(4262):330-332. doi:10.1126/science.968485. PMID: 968485. (Seminal D-Ala² substitution paper — the medicinal-chemistry precedent for the exact modification (Gly²→D-Ala²) that produced Pentapeptide-18 from leu-enkephalin.)
14. Ledwoń P, Errante F, Papini AM, Rovero P, Latajka R. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry. Chem Biodivers. 2021 Feb;18(2):e2000833. doi:10.1002/cbdv.202000833. PMID: 33348441. (Cosmeceutical-peptide review with specific Pentapeptide-18 discussion; frames the evidence-quality challenge across the cosmetic-peptide category.)
15. Reddy B, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012 Aug;21(8):569-575. doi:10.1111/j.1600-0625.2012.01528.x. PMID: 22775991. (Dermatology-journal review of bioactive cosmetic oligopeptides including the neurotransmitter-affecting peptide class to which Pentapeptide-18 belongs.)
16. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23435580. (Placebo-controlled Argireline efficacy trial providing the best-characterized comparator data for the companion peptide most often stacked with Leuphasyl.)
17. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015 Feb 20;68:27-35. doi:10.1016/j.ejps.2014.12.006. PMID: 25542574. (Vehicle-formulation permeation study relevant to Pentapeptide-18 formulation science; establishes that W/O/W multiple emulsions significantly enhance small-peptide skin penetration versus simple O/W.)
18. Lim SH, Sun Y, Thiruvallur Madanagopal T, Rosa V, Kang L. Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular Modification. Sci Rep. 2018 Jan 22;8(1):1596. doi:10.1038/s41598-018-19944-4. PMID: 29358579; PMCID: PMC5778101. (Molecular-modification strategies for improving anti-wrinkle-peptide skin permeation — directly applicable to the permeation-bottleneck framing of Pentapeptide-18 delivery.)
19. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009 Sep-Oct;27(5):485-494. doi:10.1016/j.clindermatol.2009.05.013. PMID: 19695481. (Foundational dermatology-journal review of cosmeceutical peptides that contextualizes Leuphasyl within the neurotransmitter-affecting peptide category.)
20. Lipotec S.A. LEUPHASYL®: A New Pentapeptide for Expression Wrinkles. Technical dossier / formulator brochure. Barcelona: Lipotec; 2005. (Originator manufacturer dossier, widely re-cited across cosmetic industry literature; source of the 11.64% stand-alone and 24.62% Leuphasyl + Argireline combination wrinkle-depth reduction figures. Industry white paper, not peer-reviewed.)